Pembrolizumab plus chemotherapy as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: 4.5-year follow-up from the randomized phase III KEYNOTE-859 study.
- DOI
- 10.1016/j.esmoop.2026.108536
- Published
- 2026 Sep 16
- Container
- ESMO open
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.esmoop.2026.108536,
title = {Pembrolizumab plus chemotherapy as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: 4.5-year follow-up from the randomized phase III KEYNOTE-859 study.},
author = {Rha SY and Wyrwicz LS and Yañez P and Bai Y and Ryu MH and Lee J and Rivera F and Vasconcelos Alves G and Garrido M and Shiu KK and González Fernández M and Li J and Lowery MA and Çil T and Melo Cruz F and Oh DY and Wang A and Leconte P and Qin S},
year = {2026},
journal = {ESMO open},
doi = {10.1016/j.esmoop.2026.108536},
url = {https://doi.org/10.1016/j.esmoop.2026.108536}
}RIS
TY - JOUR TI - Pembrolizumab plus chemotherapy as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: 4.5-year follow-up from the randomized phase III KEYNOTE-859 study. AU - Rha SY AU - Wyrwicz LS AU - Yañez P AU - Bai Y AU - Ryu MH AU - Lee J AU - Rivera F AU - Vasconcelos Alves G AU - Garrido M AU - Shiu KK AU - González Fernández M AU - Li J AU - Lowery MA AU - Çil T AU - Melo Cruz F AU - Oh DY AU - Wang A AU - Leconte P AU - Qin S PY - 2026 JO - ESMO open DO - 10.1016/j.esmoop.2026.108536 UR - https://doi.org/10.1016/j.esmoop.2026.108536 ER -
APA
SY, R., LS, W., P, Y., Y, B., MH, R., J, L., F, R., G, V. A., M, G., KK, S., M, G. F., J, L., MA, L., T, Ç., F, M. C., DY, O., A, W., P, L., & S, Q. (2026). Pembrolizumab plus chemotherapy as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: 4.5-year follow-up from the randomized phase III KEYNOTE-859 study.. ESMO open. https://doi.org/10.1016/j.esmoop.2026.108536
Source records
- pubmed · retrieved 2026-09-25T19:40:39.237Z